kemoterapiprogram, som er forbundet med en incidens af febril neutropeni på 10- 20% (100 mg/ m3 læ
th au In a placebo-controlled, double blind study in patients with breast cancer the effect of pegfilgrastim on the incidence of febrile neutropenia was evaluated following administration of a chemotherapy er regimen associated with a febrile neutropenia rate of 10-20% (docetaxel 100 mg/ m2 every 3 weeks for ng 4 cycles).